BioSpace News Archive

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced it has received clearance from the U.S. Food and Drug Administration for its Omnipod® 5 Automated Insulin Delivery System for individuals aged six years and older with type 1 diabetes.

LAVA Therapeutics N.V., a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, announced that Stephen Hurly, president and chief executive officer, will present the latest company overview at the SVB Leerink 11th Annual Global Healthcare Conference 2022.

AVROBIO, Inc. announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen’s 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022.

Alterity Therapeutics today announced that data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson’s Disease. MSA is a devastating neurodegenerative disorder without approved therapy.

Nutriband Inc. announced the receipt of an Issue Notification from the United States Patent and Trademark Office for its United States patent entitled, “Abuse and Misuse Deterrent Transdermal System,” that protects its AVERSA™ transdermal abuse deterrent technology.

I-Mab announced the signing of a partnership agreement with the Hangzhou Qiantang New Area in China to manufacture its innovative drugs locally and accelerate its transition to commercialization.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced its late-stage preclinical Mpro inhibitor, STI-1558, effectively inhibits Omicron virus entry and replication in cell-based assays.

Recently, Nanjing Bioheng Biotech Co., Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for the treatment of gastric cancer.

Procaps Group, a leading integrated international healthcare and pharmaceutical company, announced the appointment of Melissa Angelini as Investor Relations Director, effective February 1, 2022.

Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, “Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children.”